In evaluating the Theranos Fraud Case, why didn’t the Theranos compliance program meet the spirit and intent of the following DOJ guideline questions:
In evaluating the Theranos Fraud Case, why didn’t the Theranos compliance program meet the spirit and intent of the following DOJ guideline questions: “Is the corporation’s compliance program well designed?” “Is the program being applied earnestly and in good faith?” In other words, is the program being implemented effectively? “Does the corporation’s compliance program work […]